Anthem Biosciences

ANTHEM · NSE

— · —

₹869.75

Closing price — 29 Sept 2026

Market cap ₹48,990 Cr · EPS ₹4.83

Valuation

Blended fair value using DCF and peer comparison methods.

See if Anthem Biosciences is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Contract research & manufacturing · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Anthem Biosciences ANTHEM · you	₹49,883 Cr	84.3×	16.2×	61.7×	19.5%	27.9%	26.2%
Sector median	—	58.5×	5.5×	37.6×	13.5%	14.5%	10.8%
Laurus Labs LAURUSLABS	₹76,900 Cr	85.5×	14.3×	43.4×	16.8%	13.0%	4.1%
Sai Life Sciences SAILIFE	₹26,076 Cr	74.8×	10.5×	41.9×	14.0%	15.9%	21.7%
Neuland Laboratories NEULANDLAB	₹22,034 Cr	60.6×	11.8×	38.6×	19.4%	18.0%	19.3%
Granules India GRANULES	₹18,955 Cr	31.3×	3.7×	16.4×	11.7%	11.1%	5.9%
Syngene International SYNGENE	₹18,242 Cr	56.5×	3.7×	20.2×	6.5%	8.5%	5.4%
Caplin Point Laboratories CAPLIPOINT	₹17,160 Cr	25.1×	4.5×	22.6×	17.9%	29.3%	14.2%
Cohance Lifesciences COHANCE	₹16,515 Cr	92.3×	4.2×	41.7×	4.6%	7.9%	19.2%
Concord Biotech CONCORDBIO	₹13,302 Cr	51.3×	6.6×	36.5×	12.9%	24.7%	7.3%

Peer comparison verdict

Anthem trades at a premium to peers (P/E 82.8× vs median 58.5×), but its higher ROE of 19.5% (sector 13.5%) justifies much of that premium — quality rarely comes cheap.

Business quality

Valuation

P/E ratio

82.8×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

19.5%

ROCE

21.8%

ROA

—

Growth

Revenue CAGR (3yr)

26.2%

EPS CAGR (3yr)

15.4%

Efficiency

Asset turnover

—

FCF yield

1.3%

Dividend yield

0.2%

Liquidity & Solvency

Debt / Equity

0.01×

Debt / EBITDA

—

Interest coverage

98.0×

Current ratio

5.54×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Is the business financially healthy?

Two structured frameworks that go beyond a single number to assess financial strength.

Altman Z-Score

Predicts likelihood of financial distress. Above 2.99 = safe zone; 1.81–2.99 = grey zone; below 1.81 = distress.

69.79

Safe zone

0 (distress)2.99 (safe)5+

Piotroski F-Score

6 / 9 — Moderate

Nine binary checks across profitability, leverage/liquidity, and operating efficiency. 7+ = financially strong; 4–6 = average; 0–3 = weak signals.

Profitability (1–4)

Leverage (5–7)

Efficiency (8–9)

Positive net income

Positive operating cash flow

Improving return on assets

Cash flow exceeds net income

Debt ratio reduced

Improving current ratio

No equity dilution

Improving gross margin

Improving asset turnover

See if Anthem Biosciences is financially healthy

Unlock financial health scores for 4,800+ Indian stocks — free.

Calculated from annual report data sourced via BSE/NSE filings. For precise figures refer to BSE/NSE filings.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹2,124 Cr

Net profit

₹592 Cr

Operating margin

—

Net margin

27.9%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

₹844.49 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

₹633.32 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹28 Cr

Equity

₹3,043 Cr

Debt / Equity

0.01×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

74.7%

-0.0 pp QoQ

FII

1.3%

-0.1 pp QoQ

DII

11.6%

+4.0 pp QoQ

Retail

12.5%

Trend over time (%)

Quarterly data

Category	Sep 2025	Dec 2025	Mar 2026	Change (YoY)
Promoter	74.7%	74.7%	74.7%	-0.0 ppvs oldest
FII (Foreign)	1.7%	1.4%	1.3%	-0.4 ppvs oldest
DII (Domestic)	7.2%	7.6%	11.6%	+4.3 ppvs oldest
Retail	16.4%	16.3%	12.5%	-3.9 ppvs oldest

Signals from the trend

➡️

PromoterStable — no notable buying or selling

➡️

FIIStable

📈

DIINet buyers (+4.3pp) — domestic funds are accumulating

Overall positive — DII buying suggest growing conviction in the business.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.